Joint Commission keeping clinician texting ban in place until September

After reversing a five-year-old ban on healthcare organizations sending orders via text in May, the Joint Commission has changed plans again, announcing in its June newsletter the previous ban won’t be lifted until September.

The commission said extra guidance is needed to “ensure a safe implementation involving the secure texting of orders” for organizations interested in using that kind of system.

“The Centers for Medicare & Medicaid Services (CMS) will collaborate with the Joint Commission on the development of additional guidance for text orders to ensure congruency with the Medicare Conditions of Participation,” the commission said. “The Joint Commission and CMS will develop a comprehensive series of frequently asked questions (FAQ) documents to assist healthcare organizations with the incorporation of text orders into their policies and procedures.”

The May update had included several suggestions for setting up a secure texting platform, such as a secure sign-on process and limiting who can receive and record the orders, but the commission had also said more detailed standards would have to be developed. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.